NATF 10th Anniversary Celebration
We would like to thank everyone who came out for this inspiring evening at the Mandarin Oriental Hotel to celebrate a decade of fighting blood clots and saving lives through prevention and education!
For those who were not able to attend, we invite you to watch our 10th Anniversary Celebration video recounting all of the wonderful things NATF has accomplished over the past ten years:
The American Journal of Medicine published the NATF Atrial Fibrillation Action Initiative consensus document in April 2016. This document presents usable recommendations on stroke prevention, bleeding risk assessment, and anticoagulation management based off clinical trial data and guideline updates for Afib. Please visit the AFib section of our website to learn more.
2016 THROMBOSIS SUMMIT
Saturday, October 1
7:00 AM - 12:00 PM
Fairmont Copley Plaza Hotel, Boston, MA
This special half-day program is designed for physicians, pharmacists, nurses, nurse practitioners, physician assistants,and allied health professionals. Patients, family members and caregivers are also encouraged to attend.
Earn up to 3.5 CME credits for attendance
Experts in the field of Thrombosis Medicine will share updates from breakthrough research that has been completed over the last year on blood clots including heart attack, stroke as a result of atrial fibrillation, pulmonary embolism, and deep vein thrombosis.
Three patient survivors of major thrombotic events will provide their perspective, recounting their experience from initial symptoms and diagnosis through treatment to recovery. Reserve your seat now!
Space Still Available!
5th Regional AC Forum Bootcamp
October 6-7, 2016
Hotel Albuquerque at Old Town
This compact 2-day meeting provides a comprehensive curriculum that covers the essential aspects of anticoagulation,disease state, and drug management. Engaging discussion around quality improvement, new agents and special situations will benefit all practicioners and daily "chalk talks" will allow for attendee participation to shape the topics.
For more information or to register visit
DVT/PE TREATMENT OPTIONS
How do healthcare providers decide which treatments are the best option for their patients? Read this article to find out more about DVT/PE treatment goals, options, risks, and decision-making.
For many years, Warfarin was the only oral anticoagulant commonly used to treat blood clots. In the past five years, the FDA has approved four new oral anticoagulants for the treatment of DVT, PE, and SPAF. Find out the differences between the five FDA-approved oral anticoagulants. View the Chart.